With a proven team of world experts across multiple company functions, leading healthcare investors and proprietary health technology tools, we are well-positioned to rapidly advance our clinical-stage pipeline and create value for patients, health systems and investors. While Novo Nordisk and Eli Lilly are currently the dominant players in the weight-loss drug market, other companies have been trying to get into the race and take a slice of the pie
Pharmacology Biochemistry and Behavior 150: 3947
Nielsen R, Srensen S, Birn BS, Christensen H, Nex EI
Curr Opin Pharmacol (2020) 54:91101
Severe low testosterone symptoms may necessitate starting with TRT, while significant weight loss goals might prioritize a GLP-1 like semaglutide. One of the biggest concerns when starting two medications at the same time is that if a side effect occurs, it can be difficult to know which one caused it, says Staheli